Ming-yu Luo
Shanghai, 200025, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Metabolic enzyme-associated protein-protein interactions (mPPIs) in cancer: potential vulnerability for cancer treatment?
Journal: Acta pharmacologica Sinica
Published: January 14, 2025
A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression.
Journal: Acta pharmaceutica Sinica. B
Published: March 17, 2024
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: December 20, 2022
Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Journal: Cancer research
Published: November 28, 2021
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Journal: Acta pharmacologica Sinica
Published: January 05, 2020
Pilot study on efficacy of reduced cathartic bowel preparation with polyethylene glycol and bisacodyl.
Journal: World journal of gastroenterology
Published: October 30, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026